[Tissue and serum levels of 5-FU in the patients with head and neck malignant tumors--influence of a streptococcal preparation OK-432].
Concentrations of Tegafur, 5-FU, and Uracil were measured in the tissues and serum of 32 patients with malignant head and neck tumors after administration of UFT or UFT and OK-432. Of the 32 patients, 15 patients were treated with UFT alone and 17 patients with a combination of UFT and a clinical dose of OK-432. The level of 5-FU was higher in the tissues and serum in the patients who received the combined administration of UFT and OK-432 than in those the received UFT alone. In particular, levels of 5-FU in tumor tissue and metastatic lymph node tissue were higher than 0.05 micrograms/g even 14.6 hours after the last administration of UFT. No significant undesirable interactions between UFT and OK-432 were exhibited during combination therapy of these agents in clinically administered doses. From our satisfactory results, clinical cures would be expected by the combined immuno-chemotherapeutic action of these agents.
Suzuki
K
K
Dept. of Otolaryngology, Nagoya City University Medical School.
Itaya
S
S
Tsuge
I
I
Matsuda
T
T
Motai
H
H
Kobayashi
T
T
Shimada
J
J
Baba
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000493:pharmacokinetics* / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000032:analysis / Q000097:blood*; D006258:Head and Neck Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000008:administration & dosage*; D005641:Tegafur / Q000008:administration & dosage / Q000493:pharmacokinetics; D014498:Uracil / Q000008:administration & dosage / Q000493:pharmacokinetics
D005641:Tegafur; D010844:Picibanil; D014498:Uracil; D005472:Fluorouracil